Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections

Çetin, Ebru; Demirtaş, Önder; Özbakış, Nihal Cesur; Pekel, Gökhan

doi:10.1007/s00417-018-4042-5

Cited by 3 publications

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We still assume that this difference may be caused by distinct mechanisms of ERM formation. Previous studies have stated that anti-VEGF agents may be involved in the fibrotic process of diabetic eyes, induced by the intravitreal injection method or angio-fibrotic switch of VEGF and CTGF in PDR [24]. Besides, long-term intravitreal injection attributing to repetition of volume expansion may accelerate posterior vitreous detachment, which is beneficial in the natural history of DME [25].…”

Section: Discussionmentioning

confidence: 99%

Change of Optical Coherence Tomography Morphology and Associated Structural Outcome in Diabetic Macular Edema after Ranibizumab Treatment

Chen

Lai

Lee

et al. 2022

JPM

View full text Add to dashboard Cite

(1) Background: To investigate the correlation between therapeutic outcome and morphologic changes for diabetic macular edema (DME) after intravitreal injection of ranibizumab (IVIR). (2) Methods: This retrospective study included 228 eyes received IVIR for DME. Each participant was traced for two years after the initial IVIR, while the data of ophthalmic examination, optical coherence tomography (OCT) image, and systemic diseases were collected. The study population was categorized into different subgroups according to the existence of OCT morphologic change and the initial OCT morphologic pattern, including diffuse retinal thickening (DRT), cystoid macular edema (CME), serous retinal detachment (SRD), and vitreomacular interface abnormalities (VMIAs). The primary outcomes were the baseline best-corrected visual acuity (BCVA) and central macular thickness (CMT) during a two-year study period. The distribution of OCT morphologic change and its relation to primary outcome were analyzed. (3) Results: Comparing the 42 eyes (18.4%) with OCT morphological changes to another 186 eyes (81.6%) without such alteration, the former showed a poorer baseline BCVA (0.84 ± 0.39 vs. 0.71 ± 0.36, p = 0.035), worse final BCVA (0.99 ± 0.44 vs. 0.67 ± 0.30, p = 0.001), and thicker final CMT (354.21 ± 89.02 vs. 305.33 ± 83.05, p = 0.001). Moreover, the VMIA developed in 14.9% of all DME patients presenting the most common morphologic change among DRT, CME, and SRD. Besides, the presence of stroke was independently correlated to the morphologic change (adjusted odds ratio [aOR]: 6.381, 95% confidence interval (CI): 1.112–36.623, p = 0.038). (4) Conclusions: The change of OCT morphology in DME patients receiving IVIR was correlated to worse structural and visual outcome while the formation of VMIA most commonly occurred after initial treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Change of Optical Coherence Tomography Morphology and Associated Structural Outcome in Diabetic Macular Edema after Ranibizumab Treatment

Chen

Lai

Lee

et al. 2022

JPM

View full text Add to dashboard Cite

show abstract

The effects of epiretinal membranes on the treatment outcomes of intravitreal aflibercept injection in diabetic macular edema: a real-life study

Altıntaş

İlhan²,

Cankurtaran

2020

Int Ophthalmol

View full text Add to dashboard Cite

Assessment of Vitreoretinal Interface Alterations in Diabetic Macular Edema Treated With Intravitrealantivegf Injections

Wani

Lone

Khan

2022

IJAR

View full text Add to dashboard Cite

Background : The introduction of anti-VEGF therapy has had a greater effect on the world of retina than any other advance in the past few decades. This study was conducted to see whether anti-VEGF agents have any kind of brotic effect for the development of vitreomacular interface abnormalities, in diabetic eyes without pre-existing brotic membranes. Materials and Methods: This study was a Hospital based retrospective observational study, conducted in the Department of Ophthalmology, SKIMS Medical College Hospital, Srinagar.100 eyes were included in the study. Patients with DME followed at least 9 months were reviewed. Patients were divided into two groups: 50 eyes in anti-VEGF group that had DME and received intravitreal injections and 50 eyes in control group without signicant central DME. The groups were comparable in terms of diabetes duration and HbA1c. Results: Atotal of 100 eyes were taken in the study that met the inclusion criteria. Vitreomacular interface abnormalities (VMIA) (ERM, VMT and Macular hole) developed in 11 (22%) of the eyes during a follow up period of 36 weeks as compared to 2 eyes (4%) of the control group. This difference is statistically signicant (p = 0.015). Poor baseline vision was found to be a risk factor for VMIAdevelopment. Conclusion: Our study revealed that patients with clinically signicant DME who underwent intravitreal injections had a rate of vitro macular interface abnormalities formation in 22% of eyes during a follow up period of 9 months as compared to 4% eyes of the control group. This difference was statistically signicant. VMIA changes in the eyes was associated with initial poor vision. Improvement of BCVA and Central Macular Thickness at the nal visit compared with baseline in eyes treated with intravitreal anti-VEGFs was statistically signicant.

show abstract

Quantitative assessment of macular contraction and vitreoretinal interface alterations in diabetic macular edema treated with intravitreal anti-VEGF injections

Abstract: There was a displacement of macular capillary vessels which was associated with the change in macular thickness in eyes having anti-VEGF injections for DME. The number of ERM cases did not change significantly during the follow-up.

Cited by 3 publications

References 36 publications

Change of Optical Coherence Tomography Morphology and Associated Structural Outcome in Diabetic Macular Edema after Ranibizumab Treatment

Change of Optical Coherence Tomography Morphology and Associated Structural Outcome in Diabetic Macular Edema after Ranibizumab Treatment

The effects of epiretinal membranes on the treatment outcomes of intravitreal aflibercept injection in diabetic macular edema: a real-life study

Assessment of Vitreoretinal Interface Alterations in Diabetic Macular Edema Treated With Intravitrealantivegf Injections

Contact Info

Product

Resources

About